[35S]guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: Actions of antiparkinsonian and antipsychotic agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 181-191

  Newman Tancredi, A ^a,b   Audinot, V ^a   Chaput, C ^a   Verriele L ^a   Millan, M J ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 2 [4 [4,4 BIS(4 FLUOROPHENYL)BUTYL] 1 PIPERAZINYL]PYRIDINE 3 CARBOXYLIC ACID; 2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 3 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL 1H PYRROLO[2,3 B]PYRIDINE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 4' ACETYL N [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BIPHENYL 4 CARBOXAMIDE; 4' ACETYL N4 [(2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYLBIPHENYL 4 CARBOXAMIDE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; ANTIPARKINSON AGENT; BROMOCRIPTINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; FANANSERIN; FG 5893; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; LEVODOPA; LISURIDE; NEUROLEPTIC AGENT; OCAPERIDONE; OLANZAPINE; PERGOLIDE; PIRIBEDIL; QUETIAPINE; QUINEROLANE; RACLOPRIDE; ROPINIROLE; SERTINDOLE; SPIPERONE; SULFUR 35; TERGURIDE; TIOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRD4 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; MAGNESIUM CHLORIDE; RECOMBINANT PROTEIN; SODIUM CHLORIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG POTENCY; DRUG RECEPTOR BINDING; MEMBRANE BINDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; ANIMAL; BINDING COMPETITION; DRUG EFFECT; HAMSTER; HUMAN; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; HUMANS; MAGNESIUM CHLORIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECOMBINANT PROTEINS; SODIUM CHLORIDE; SPIPERONE;

EID: 0030610721     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. 1B receptor expression system. Mol. Pharmacol. 43: 427-433, 1993.
2. 2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann. Neurol. 33: 507-511, 1993.
3. 4 receptor variants. J. Neurochem. 65: 1157-1165, 1995.
4. 4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46: 364-373, 1994.
5. 1 adenosine receptors in human myocardium. Am. J. Physiol. 266: H1951-H1958, 1991.
6. BORNANCIN, F., PFISTER, C. AND CHABRE, M.: The transitory complex between photoexcited rhodopsin and transducin. Eur. J. Biochem. 184: 687-689, 1989.
7. BOUVIER, C., BUNZOW, J. R., GUAN, H.-C., UNTEUTSCH, A., CIVELLI, O., GRANDY, D. K. AND VAN TOL, H. H. M.: Functional characterization of the human dopamine D4.2 receptor using vaccinia virus as an expression system. Eur. J. Pharmacol. 290: 11-17, 1995.
8. 2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci. Lett. 181: 65-68, 1994.
9. 4 receptors. J. Neurochem. 63: 62-65, 1994.
10. 4 receptor locus. Hum. Genet. 98: 91-101, 1996.
11. 3 dopamine receptors in human striatum. Prog. NeuroPsychopharmacol. Biol. Psychiat. 19: 1147-1154, 1995.
12. 2 receptor antagonist. Br. J. Pharmacol. 105: 27-36, 1992.
13. 4 receptor? Life Sci. 57: 275-283, 1995.
14. FACTOR, S. A., MOHLO, E. S., PODSKALNY, G. D. AND BROWN, D.: Parkinson's disease: drug induced psychiatric states. Adv. Neurol. 65: 115-138, 1995.
15. FILIPOVA, M., FILIP, V., MACEK, Z., MULLEROVA, S., MARKOVA, J., KAS, S., ZIZKOVA, B., KRIVKA, J., VOTAVOVA, M. AND KREJCOVA, H.: Terguride in Parkinsonism: A multicenter trial. Eur. Arch. Psychiatry Neurol. Sci. 237: 298-303, 1988.
16. 1-adenosite receptors with G-proteins: Reciprocal modulation of agonist and antagonist binding. Biochem J. 275: 651-656, 1991.
17. GIERSCHIK, P., MOGHTADER, R., STRAUB, C., DIETERICH, K. AND JAKOBS, K. H.: Signal amplification in HL-60 granulocytes. Eur. J. Biochem. 197: 725-732, 1994.
18. GOLDSTEIN, J. M.: Pre-clinical pharmacology of the new atypical antipsychotics in late stage development. Exp. Opin. Invest. Drugs 4: 291-298, 1995.
19. HEUILLET, E., PETITET, F., MIGNANI, S., MALLERON, J.-L., LAVAYRE, J., NÉLIAT, G., DOBLE, A. AND BLANCHARD, J.-C.: The naphtosultam derivative RP62203 (fananserin) has high affinity for the dopamine D4 receptor. Eur. J. Pharmacol. 314: 229-234, 1996.
20. HILF, G., GIERSCHIK, P. AND JAKOBS, K. H.: Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guaninenucleotide-binding proteins in cardiac membranes. Eur. J. Biochem. 186: 725-731, 1989.
21. HORNYKIEWICZ, O.: Brain catecholamines in schizophrenia: A good case for noradrenaline. Nature 299: 484-486, 1982.
22. JENNER P.: The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45: suppl. 3, S6-S120, 1995.
23. KENAKIN T.: The classification of seven transmembrane receptors in recombinant expression systems Pharmacol. Rev. 48: 413-463, 1996.
24. KHURANA, M. L. AND PANDEY, K. N.: Catalytic activation of guanylate cyclase/atrial natriuretic factor receptor by combined effects of ANF and GTPγS in plasma membranes of Leydig tumor cells: Involvement of G-proteins. Arch. Biochem. Biophys. 316: 392-398, 1995.
25. 4 antagonist (L 745870) in acutely psychotic schizophrenic patients. New Clinical Drug Evaluation Unit, 36th Annual Meeting, Boca Raton, FL, poster 106, 1996.
26. 4 receptor. J. Med. Chem. 39: 1941-1942, 1996.
27. 2c receptor in Sf9 cells. Mol. Pharmacol. 48: 150-159, 1995.
28. 4.4 receptors. Eur. J. Pharmacol. 301: R11-R13, 1996.
29. 2-family receptors in human postmortem brain sections: Comparison of receptor densities between normals and schizophrenics off and on neuroleptics (Abstract). Am. Soc. Neurosci. 21: 636.4, 1995.
30. 4.4 receptor. J. Neurochem. 68: 804-812, 1997.
31. LAWSON, C. F., MORTIMORE, R. A., SCHLACHTER, S. K. AND SMITH, M. W.: Pharmacology of a dopamine D4 receptor expressed in HEK293 cells. Methods Find. Exp. Clin. Pharmacol. 16: 303-307, 1994.
32. LAZARENO, S., FARRIES, T. AND BIRDSALL, N. J. M.: Pharmacological characterisation of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors ml-m4. Life Sci. 52: 449-456, 1993.
33. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89: 8155-8159, 1992.
34. LICHTER, J. B., BARR, C. L., KENNEDY, J. L., VAN TOL, H. H. M., KIDD, K. K. AND LIVAK, K. J.: A hyper-variable segment in the human dopamine receptor D4 (DRD4) gene. Hum. Mol. Genet. 2: 797-763, 1993.
35. 35S]thio)triphosphate binding. Mol. Pharmacol. 44: 115-123, 1993.
36. 1 adenosine receptor with receptor/G-protein complexes in rat brain membranes. Mol. Pharmacol. 49: 915-926, 1996.
37. MATSUMOTO, M., HODAKA, K., TADA, S., TASAKI, Y. AND YAMAGUCHI, T.: Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J. Neurochem. 66: 915-919, 1996.
38. 4 dopamine receptor in a stable human cell line. FEBS Lett. 345: 147-150, 1994.
39. MEADOR-WOODRUFF, J. H., DAMASK, B. S., WANG J., HAROUTUNIAN, V., DAVIS, K. L. AND WATSON, S. J.: Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15: 17-29, 1996.
40. MELTZER H. Y.: Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br. J. Psychiatry 168: suppl. 29, 23-31, 1996.
41. MELTZER, H. Y., KENNEDY, J., DAI, J., PARSA, M. AND RILEY, D.: Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine. Neuropsychopharmacology 12: 39-45, 1995.
42. 2 receptors, and an atypical antipsychotic profile in the rat. Br. J. Pharmacol. 114: suppl., 156P, 1995.
43. 4 dopamine receptors in baculovirus-infected insect cells. FEBS Lett. 320: 130-134, 1993.
44. 4 receptors in GABAergic neurons of the primate brain. Nature 381: 245-248, 1996.
45. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-2191, 1995a.
46. 3 receptor. Bioorg. Med. Chem. Lett. 5: 219-222, 1995b.
47. 4 receptors. Eur. J. Pharmacol. 319: 379-383, 1997a.
48. 1A receptors. Neuropharmacology 35: 119-121, 1996a.
49. 1A receptors. Eur. J. Pharmacol. 307: 107-111, 1996b.
50. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br. J. Pharmacol. 120: 737-740, 1997b.
51. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacol 36: 451-459, 1997c.
52. 4 receptors. J. Pharmacol. Exp. Ther. 277: 186-192, 1996.
53. OLBRICH R. AND SCHANZ H.: The effect of the partial dopamine agonist, terguride, on negative symptoms in schizophrenics. Pharmacopsychiatry 21: 389-390, 1988.
54. OLBRICH R. AND SCHANZ H.: An evaluation of the partial dopamine agonist, terguride, regarding positive symptoms reduction in schizophrenics. J. Neural Transm. 84: 233-236, 1991.
55. sα. Biochemistry 32: 11064-11073, 1993.
56. 4 receptors in schizophrenia? J. Neurochem. 66: 881-882, 1996.
57. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120: 365-368, 1995.
58. SCHOTTE, A., JANSSEN, P. F. M., GOMMEREN, W., LUYTEN, W. H. M. L., VAN GOMPEL, P., LESAGE, A. S., DE LOORE, K. AND LEYSEN, J. E.: Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124: 57-73, 1996.
59. 4 receptors elevated in schizophrenia. Nature 365: 441-445, 1993a.
60. 4 receptors in Parkinson's, schizophrenia, and control brain striata. Synapse 14: 247-253, 1993b.
61. SIM, L. J., SELLEY, D. E., XIAO, R. AND CHILDERS, S. R.: Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307: 97-105, 1996.
62. 1. Nature 350: 614-619, 1991.
63. D4 dopamine receptors in fibroblast and dopaminergic cell lines. J. Pharmacol. Exp. Ther. 268: 495-502, 1994.
64. TAYLOR, D. P. AND DEKLEVA, J.: Potential antipsychotic BMY-14802 selectively binds to sigma sites. Drug Dev. Res. 11: 65-70, 1987.
65. 1D receptor subtypes. J. Recept. Signal Transduct. Res. 15: 199-211, 1995.
66. 2-adrenergic activation of G proteins: Evidence for a precoupled receptor/G-protein state. Mol. Pharmacol. 45: 524-531, 1994.
67. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47: 848-854, 1995.
68. VAN KAMMEN D., PETERS J., YAO J., VAN KAMMEN W. B., NEYLAN T., SHAW D. AND LINNOILA M.: Norepinephrine in acute exacerbations of chronic scizophrenia. Arch. Gen. Psychiatry 47: 161-168, 1990.
69. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991.
70. VAN TOL, H. H. M., Wu, C. M., GUAN, H.-C., OHARA, K, BUNZOW, J. R., CIVELLI, O., KENNEDY, J., SEEMAN, P., NIZNIK, H. B., JOVANOVIC, V.: Multiple dopamine D4 receptor variants in the human population. Nature 358: 149-152, 1992.
71. WEDDELL, R. A. AND WEISER, R.: A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition and mood in de novo patients with Parkinson's disease. Behav. Pharmacol. 6: 81-91, 1995.
72. 4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol. Pharmacol. 49: 656-661, 1996.
73. WOLTERS, E. C., TISSINGH, G., BERGMANS, P. L. M. AND KUIPER, M. A.: Dopamine agonists in Parkinson's disease. Neurology 45: suppl 3, S28-S34, 1995.